FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Clinical Hold Slapped on Kezar Lupus Trial

FDA orders a clinical hold on Kezar Life Sciences IND for zetomipzomib and its investigational use in treating lupus nephritis.

latest-news-card-1
Human Drugs

Sublocade Priority Review for Expanded Labeling

FDA awards a priority review for an Indivior prior approval supplement for Sublocade (buprenorphine) extended-release injection for treating moderate ...

Medical Devices

AdvaMed Seeks FDA Best Practice on Trial Diversity

AdvaMed says that as FDA begins receiving and reviewing diversity action plans, it should publicly disclose any key best practices it identifies.

latest-news-card-1
Human Drugs

Comments Sought on Pharmaceutical Quality Terminology

FDA requests comments on a draft document about controlled terminology/vocabulary that applies to a set of coded quality attribute data elements for t...

latest-news-card-1
Medical Devices

Medtronic Recalls MiniMed Pumps Over Batteries

Medtronic recalls (Class 1) its MiniMed Insulin pumps due to concerns about reduced battery life in certain situations.

latest-news-card-1
Medical Devices

FDA Clears PlaqueIQ for Cardiovascular Disease

An Elucid 510(k) gains clearance for its PlaqueIQ imaging analysis software to help physicians diagnose cardiovascular disease.

latest-news-card-1
Human Drugs

Thermo Fisher Plant Scrutinized by FDA: Reuters

A Reuters article looks into drug GMP issues raised by FDA inspections over the past decade at Thermo Fisher's Greenville, NC drug contract manufactur...

latest-news-card-1
Medical Devices

CDRH Portal Update Tracks PMA Submissions

FDA updates CDRHs Customer Collaboration Portal to track the progress of PMA applications and accept Small Business Determination requests.

latest-news-card-1
Human Drugs

Drug-Drug Interaction Assessments Lacking: FDA Research

FDA says that 22% of new molecular entities required postmarketing requirements or postmarketing commitments to address knowledge gaps on drugdrug int...

latest-news-card-1
Human Drugs

J&J Discontinues Dengue Virus Antiviral Development

Johnson & Johnson discontinues a Phase 2 study evaluating mosnodenvir for preventing dengue virus in adults aged 18-65 years.